Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

French (CAC) Pharma Industry Analysis

UpdatedApr 03, 2026
DataAggregated Company Financials
Companies6
  • 7D2.5%
  • 3M3.8%
  • 1Y-11.6%
  • YTDn/a

Over the last 7 days, the Pharma industry has risen 4.0%, driven by gains from Sanofi of 1.8%. In the past year, the industry is down 12%. Earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the French Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 03 Apr 2026€117.9b€54.0b€5.4b20.2x21.8x2.2x
Sun, 01 Mar 2026€117.6b€54.0b€5.5b23.3x21.5x2.2x
Tue, 27 Jan 2026€112.7b€53.0b€7.0b23x16.2x2.1x
Thu, 25 Dec 2025€113.8b€53.0b€7.0b22x16.3x2.1x
Sat, 22 Nov 2025€120.1b€53.0b€7.0b22.5x17.2x2.3x
Mon, 20 Oct 2025€119.1b€52.9b€6.9b21x17.2x2.3x
Wed, 17 Sep 2025€109.8b€52.8b€6.9b19.7x15.9x2.1x
Fri, 15 Aug 2025€115.4b€52.8b€6.9b19.1x16.7x2.2x
Sun, 13 Jul 2025€114.4b€52.1b€6.7b19.7x17.2x2.2x
Tue, 10 Jun 2025€119.5b€52.1b€6.7b18.8x17.9x2.3x
Thu, 08 May 2025€124.1b€52.1b€6.7b17.9x18.6x2.4x
Sat, 05 Apr 2025€130.0b€51.2b€5.9b17.6x21.8x2.5x
Mon, 03 Mar 2025€144.1b€51.2b€5.8b18.3x24.9x2.8x
Wed, 29 Jan 2025€140.6b€55.2b€5.1b18.8x27.6x2.5x
Fri, 27 Dec 2024€128.2b€55.2b€5.1b19.2x25.2x2.3x
Sun, 24 Nov 2024€130.3b€55.2b€5.1b19.9x25.6x2.4x
Tue, 22 Oct 2024€139.3b€53.8b€4.8b20.6x29x2.6x
Thu, 19 Sep 2024€143.3b€53.9b€4.8b20.8x29.8x2.7x
Sat, 17 Aug 2024€137.4b€53.8b€4.8b20.4x28.6x2.6x
Mon, 15 Jul 2024€132.3b€52.9b€5.2b20.9x25.6x2.5x
Wed, 12 Jun 2024€127.4b€52.9b€5.2b21.9x24.6x2.4x
Fri, 10 May 2024€131.3b€52.9b€5.2b20.7x25.4x2.5x
Sun, 07 Apr 2024€122.9b€52.7b€6.0b20.2x20.3x2.3x
Tue, 05 Mar 2024€121.9b€52.6b€6.0b20.1x20.2x2.3x
Thu, 01 Feb 2024€131.3b€52.2b€9.7b20.2x13.5x2.5x
Sat, 30 Dec 2023€127.0b€52.2b€9.7b19x13.1x2.4x
Mon, 27 Nov 2023€121.6b€52.2b€9.7b17.4x12.5x2.3x
Wed, 25 Oct 2023€137.0b€52.6b€9.3b15.6x14.8x2.6x
Fri, 22 Sep 2023€144.0b€52.6b€9.3b18.5x15.5x2.7x
Sun, 20 Aug 2023€137.8b€52.6b€9.3b21.1x14.9x2.6x
Tue, 18 Jul 2023€131.7b€52.6b€9.1b17.2x14.4x2.5x
Thu, 15 Jun 2023€131.7b€52.6b€9.1b15.4x14.4x2.5x
Sat, 13 May 2023€138.7b€52.6b€9.1b15.7x15.2x2.6x
Mon, 10 Apr 2023€141.8b€51.8b€9.2b15.3x15.5x2.7x
Price to Earnings Ratio

15.5x


Total Market Cap: €141.8bTotal Earnings: €9.2bTotal Revenue: €51.8bTotal Market Cap vs Earnings and Revenue0%0%0%
French Pharma Industry Price to Earnings3Y Average 19.7x202420252026
Current Industry PE
  • Investors are optimistic on the French Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 21.9x which is higher than its 3-year average PE of 19.7x.
  • The industry is trading close to its 3-year average PS ratio of 2.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 16% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does French Pharma compare with similar industries?

FR Market2.66%
Healthcare1.61%
Pharma2.53%
Pharma2.53%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SAN Sanofi€82.581.8%
+€1.7b		-17.2%PE20.2x
IPN Ipsen€167.509.6%
+€1.2b		55.4%PE31x
BOI Boiron€28.009.4%
+€41.7m		11.3%PE25.1x
MEDCL MedinCell€23.105.0%
+€39.5m		65.9%PS25.6x
AB AB Science€1.182.4%
+€2.0m		-13.3%PS84x

Latest News

SAN
€82.58
Sanofi
7D
1.8%
1Y
-17.2%
VETO
€78.40
Vetoquinol
7D
-2.5%
1Y
1.7%
IPN
€167.50
Ipsen
7D
9.6%
1Y
55.4%

IPN: Early Oncology Pipeline And Safety Setbacks Will Shape Future Upside

The analyst fair value estimate for Ipsen has shifted from €143 to about €152, as analysts factor in updated price targets around €160 to €170 and recent rating changes that reflect both the impact of the tazemetostat withdrawal and a focus on the broader pipeline and earnings profile. Analyst Commentary Recent research shows a split view on Ipsen, with some bullish analysts lifting price targets toward €160 to €170, while more cautious voices highlight pipeline depth and valuation risks after the tazemetostat withdrawal.
MEDCL
€23.10
MedinCell
7D
5.0%
1Y
65.9%

MEDCL: 2026 Revenue Ramp And Schizophrenia Launch Will Drive Upside

Analysts now set their price target for MedinCell at €33.85, slightly below the prior €34.23. This reflects updated assumptions on long term profit margins and a higher future P/E multiple in their models.
EAPI
€1.27
Euroapi
7D
1.0%
1Y
-51.3%

EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality

Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.
AB
€1.18
AB Science
7D
2.4%
1Y
-13.3%
VIRP
€351.00
Virbac
7D
-1.3%
1Y
14.5%
ALTHX
€3.05
THX Pharma Société Anonyme
7D
1.0%
1Y
606.0%
ALDVI
€1.49
Advicenne
7D
-23.6%
1Y
-7.6%
BOI
€28.00
Boiron
7D
9.4%
1Y
11.3%

Is Boiron (EPA:BOI) Using Too Much Debt?

Dec 05
Is Boiron (EPA:BOI) Using Too Much Debt?